iStent Combination Therapy for Glaucoma and Cataracts Considering that glaucoma is the most common cause of irreversible vision loss and the third most common cause of vision loss worldwide, with cataracts and refractive error being the most prevalent causes, iStent combination therapy to treat glaucoma and cataracts has high therapeutic value.
Author: Monique Schrader
Combination IOP Reduction Therapy in Open-Angle Glaucoma
Combination IOP Reduction Therapy in Open-Angle Glaucoma GLAUCOMA BACKGROUND Globally, glaucoma is a leading cause of permanent blindness. As of 2020, about 80 million people worldwide, and 3 million Americans, are affected by glaucoma. The most common form of glaucoma is open-angle glaucoma. Unfortunately, the primary risk factor for open-angle glaucoma is
Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy
A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such
Quality of Life in Adolescent Cancer Survivors
Meta-Analysis to Determine Optimal Therapy Strategies in Macular Degeneration
Meta-Analysis Results of Clinical Trial Aimed at Determining Optimal Therapeutic Strategies for anti-VEGF Therapy in nAMD Background of this Study Neovascular age-related macular degeneration (nAMD) affects as many as 196 million people worldwide, and is a major cause of severe vision problems including blindness. Despite its prevalence, disagreements about the treatment options
Tool for evaluating real world evidence in treatment of retinal disease
Tool for Evaluating RWE in the Treatment of Retinal Disease Randomized clinical trials have long been held as the gold standard for evidence based medical practices. However, there is a growing consciousness about the value of incorporating data from real world evidence (RWE) into clinical decision making. Information from real world sources such
The Future of Glaucoma Therapy? Microneedles and the Reduction of Intraocular Pressure
The Future of Glaucoma Therapy? Microneedles and the Reduction of Intraocular Pressure Around 75 million people suffer from glaucoma, making it the world’s leading eye disorder that causes irreversible blindness. Vision loss in glaucoma patients is often accompanied by the dysfunction of the retinal ganglion cell axons. This is believed to
Sexual Dysfunction in Prostate Cancer Treatments: Survey Results
Study Results: The Effects of Sexual Dysfunction in Prostate Cancer Patients Prostate cancer is the most common cancer in males, with more than 57,000 new cases each year. It accounts for around 26% of all male cancer cases. About one in six individuals with prostate cancer has advanced disease progression. Treatment of
3-Day Surprise Question To Predict Survival Rates in Advanced Cancer Patients
3-Day Surprise Question To Predict Survival Rates in Advanced Cancer Patients Predicting survival rates in cancer patients with grave severity is crucial for both the patient, family, and doctors. Knowing this can help everyone adjust to the treatment that will be offered. If the unfortunate news is given, this can also
Retinal Nerve Fiber Layer Thickness In Alzheimer’s Disease
Retinal Nerve Fiber Layer Thickness In Alzheimer’s Disease Worldwide, nearly 50 million people live with Alzheimer’s or related dementia according to Alzheimer's Disease International (ADI). If breakthroughs are not discovered, this population could triple to 152 million by the year 2050. Alzheimer’s disease (AD) accounts for around two-thirds of all dementia
